But new research shows it's not a requirement for relationship and sexual satisfaction, two key indicators of wellbeing that ...
YD Bio Limited ("YD Bio" or the "Company") (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic ...
For individuals facing fear, uncertainty and repeated procedures associated with recurrent low-grade intermediate-risk bladder tumors, timely access to treatment can be critical. ZUSDURI, the first ...
The FLAMINGO-01 DSMB met twice in 2025, most recently in December 2025, and recommended to continue the study as is without modification. The Steering Committee also met at SABCS 2025 and discussed ...
Detailed price information for Greenwich Lifesciences Inc (GLSI-Q) from The Globe and Mail including charting and trades.
An artificial intelligence (AI) model created by integrating clinical, molecular, and histopathological data significantly improved recurrence risk stratification in hormone receptor (HR)-positive, ...
Detailed price information for Greenwich Lifesciences Inc (GLSI-Q) from The Globe and Mail including charting and trades.
In risk groups defined by American Urologic Association criteria, recurrences were reported in 8.9% of patients of the low-risk group, 11% of patients in the intermediate-risk group, 22% of those in ...
Adding one year of IMFINZI treatment to Bacillus Calmette-Guérin (BCG) induction and maintenance therapy delivered an early and sustained disease-free survival benefit vs. BCG alone WILMINGTON, Del.-- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback